Dilemmas in the diagnosis and management of antiphospholipid syndrome.
Case report published in Journal of thrombosis and haemostasis : JTH (2024)
Abstract
Antiphospholipid syndrome (APS) is characterized by thrombosis (which may be venous, arterial, or microvascular) and/or pregnancy morbidity in association with persistently positive antiphospholipid antibodies. Although thrombosis and pregnancy morbidity are the main clinical criteria for a diagnosis of APS in the revised Sapporo (Sydney) criteria, recently published American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for APS have significantly refined the diagnostic algorithm to include a scoring system clustered into 6 clinical domains (macrovascular venous thromboembolism, macrovascular arterial thrombosis, microvascular thrombosis, obstetric, cardiac valve, and hematologic). Diagnosis of APS is complicated by the fact that significant heterogeneity exists in patients' clinical presentation, underlying vascular risk factors, and methods of detecting antiphospholipid antibodies. Despite the autoimmune nature of APS, anticoagulation remains the main strategy for secondary prevention of thrombosis. Furthermore, optimal antithrombotic treatment in APS patients with arterial thrombosis remains controversial due to a paucity of data from randomized controlled studies. In this paper, we present 2 cases and highlight the diagnostic and therapeutic challenges they pose and how we approach them in the light of current evidence.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
Antiphospholipid syndrome (APS) is characterized by thrombosis (which may be venous, arterial, or microvascular) and/or pregnancy morbidity in association with persistently positive antiphospholipid antibodies. Although thrombosis and pregnancy morbidity are the main clinical criteria for a...
Why This Matters for Hirudotherapy
This review with case presentations examines diagnostic and therapeutic challenges in antiphospholipid syndrome (APS), including clinical heterogeneity, antibody detection difficulties, and controversies in antithrombotic management. The authors discuss how anticoagulation remains the main strategy for secondary prevention of thrombosis in APS, while optimal treatment for arterial thrombosis remains controversial due to limited randomized controlled trial data. The abstract contains no mention of leeches, hirudotherapy, hirudin, or leech-derived anticoagulants. There is no defensible connection to ASH's domain, as the article focuses entirely on conventional pharmaceutical management and classification criteria.
Citation
Dilemmas in the diagnosis and management of antiphospholipid syndrome.
Manning et al. · Journal of thrombosis and haemostasis : JTH, 2024
Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026